(DIR) Return Create A Forum - Home --------------------------------------------------------- MS Speaks (HTM) https://msspeaks.createaforum.com --------------------------------------------------------- ***************************************************** (DIR) MS Speaks ***************************************************** (DIR) Higher severe COVID-19 risk for patients on Ocrevus, Rituxan 1 replies (DIR) Fatal PML case in 78-year-old patient on Ocrevus monotherapy 3 replies (DIR) (Abst.) Ocrelizumab depletes T-lymphocytes more than rituximab... 0 replies (DIR) (Abst.) Shorter infusion time of ocrelizumab... 1 replies (DIR) (ACTRIMS/ECTRIMS) Some MS drugs linked with worse COVID-19 out... 0 replies (DIR) (Abst.) Effect of Ocrevus on vaccine responses in patients w/MS 0 replies (DIR) (Abst.) Adverse event profile differences between Rituxan and ... 1 replies (DIR) (Abst.) Varicella zoster immunity loss in MS patient treated w... 0 replies (DIR) (Abst.) Switching to Ocrevus in RRMS patients at risk of PML p... 0 replies (DIR) 2-hour Ocrevus infusion time OK'd in Europe 0 replies ***************************************************** (DIR) Previous Page (DIR) Next Page